Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | DRD4 | P21917 | 1/20 | 0.48 |
| ▸ | DRD3 | P35462 | 1/20 | 0.48 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.42 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.38 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14128830 | 0.83 | KMT2A (0.64) | KMT2AMAPTL3MBTL1DRD4DRD3 | |
| SCHEMBL22721453 | 0.82 | KMT2A (0.50) | KMT2AMAPTL3MBTL1DRD4DRD3 | |
| SCHEMBL22721455 | 0.82 | KMT2A (0.50) | KMT2AMAPTL3MBTL1DRD4DRD3 | |
| SCHEMBL22744558 | 0.81 | KMT2A (0.57) | KMT2AMAPTL3MBTL1DRD4DRD3 | |
| SCHEMBL8735682 | 0.81 | KMT2A (0.70) | KMT2AMAPTPDE10AALDH1A1KDM4E | |
| SCHEMBL13958875 | 0.79 | KMT2A (0.58) | KMT2AMAPTL3MBTL1DRD4DRD3 | |
| SCHEMBL14094273 | 0.79 | KMT2A (0.58) | KMT2AMAPTL3MBTL1DRD4DRD3 | |
| SCHEMBL12903054 | 0.78 | ALDH1A1 (0.48) | KMT2AMAPTL3MBTL1DRD4DRD3 | |
| SCHEMBL18434124 | 0.77 | KMT2A (0.60) | KMT2AMAPTL3MBTL1DRD4DRD3 | |
| SCHEMBL30162631 | 0.75 | KMT2A (1.00) | KMT2AMAPTPDE10AALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8378107-B2 | Heteroaryl antagonists of prostaglandin D2 receptors | PANMIRA PHARMACEUTICALS, LLC (US) | 2013-02-19 | — | — | US | disclosed |
| US-8378107-B2 | Heteroaryl antagonists of prostaglandin D2 receptors | PANMIRA PHARMACEUTICALS, LLC (US) | 2013-02-19 | — | — | US | disclosed |
| US-8378107-B2 | Heteroaryl antagonists of prostaglandin D2 receptors | PANMIRA PHARMACEUTICALS, LLC (US) | 2013-02-19 | — | — | US | disclosed |
| US-20110319445-A1 | HETEROARYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2011-12-29 | — | — | US | disclosed |
| US-20110319445-A1 | HETEROARYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2011-12-29 | — | — | US | disclosed |
| US-20110319445-A1 | HETEROARYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2011-12-29 | — | — | US | disclosed |
| WO-2010039977-A2 | HETEROARYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-04-08 | — | — | WO | disclosed |
| WO-2010039977-A2 | HETEROARYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-04-08 | — | — | WO | disclosed |
| US-20080287347-A1 | Novel Lipopeptides as Antibacterial Agents | CUBIST PHARMACEUTICALS, INC. | 2008-11-20 | — | — | US | disclosed |
| US-7408025-B2 | Lipopeptides as antibacterial agents | CUBIST PHARMACEUTICALS, INC. (US) | 2008-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287347-A1 | Novel Lipopeptides as Antibacterial Agents | CLPTM1, NGLY1, VIP | KMT2A 4561/4885MAPT 4381/4885L3MBTL1 2417/4885 |
| US-20110319445-A1 | HETEROARYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | PTGDR, PTGDR2, PTGER2 | KMT2A 4151/4885MAPT 4862/4885L3MBTL1 3778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.